Cite
HARVARD Citation
Moens, A. et al. (n.d.). P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease. Journal of Crohn's and colitis. pp. i423-i424. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Moens, A. et al. (n.d.). P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease. Journal of Crohn's and colitis. pp. i423-i424. [Online].